We have 3 of 8 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
A circulating carnitine/acylcarnitine signature may serve as a non-invasive indicator of microvascular risk, and the SLC22A5–CPT2 axis represents a potential therapeutic target.
Genetic liability to DR is associated with an increased risk of AD and is accompanied by shared expression-mediated effects and convergent neurovascular-metabolic pathways, which support the possibility that DR may serve as a clinically accessible indicator of increased neurodegenerative vulnerability.
Findings reveal that Lidd selectively targets the PFKFB3-mediated glycolytic-epigenetic axis to suppress PASMC phenotypic transformation and pulmonary vascular remodeling, positioning it as a promising therapeutic candidate for PH.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
